Julie Farand
18Patents
4h-index
59Co-inventors
59Inventor score
Filing activity: May 15, 2006 → Aug 22, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9376441B2 | Substituted pyrrolidines as SYK inhibitors | Chemistry; Metallurgy | 13 | Active |
| US11584738B2 | LPA receptor antagonists and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US11136290B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | Emerging Cross-Sectional Technologies | 4 | Active |
| US10005774B2 | Syk inhibitors | Chemistry; Metallurgy | 4 | Active |
| US11787825B2 | Therapeutic compounds for HIV virus infection | Chemistry; Metallurgy | 4 | Active |
| US11548871B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US8003661B2 | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists | Chemistry; Metallurgy | 1 | Active |
| US11912686B2 | LPA receptor antagonists and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US10329286B2 | FXR (NR1H4) modulating compounds | Chemistry; Metallurgy | 1 | Active |
| US11247986B2 | FXR (NR1H4) modulating compounds | Chemistry; Metallurgy | 1 | Active |
| US8013159B2 | Quinoline derivatives as EP4 antagonists | Human Necessities | 1 | Active |
| US12187753B2 | Therapeutics compounds for HIV virus infection | Human Necessities | 0 | Active |
| US12404262B2 | Therapeutic compounds for HIV virus infection | Chemistry; Metallurgy | 0 | Active |
| US8685999B2 | Beta carboline sulphonylurea derivatives as EP4 receptor antagonists | Human Necessities | 0 | Active |
| US11999717B2 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12358903B2 | FXR (NR1H4) modulating compounds | Chemistry; Metallurgy | 0 | Active |
| US12084467B2 | Therapeutic compounds for HIV virus infection | Chemistry; Metallurgy | 0 | Active |
| US12049439B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.